HQ

PharmaEssentia’s BESREMi (Ropeginterferon alfa-2b-njft) Now Available For the Treatment of People with PV in the United States

U.S. FDA Approves BESREMi(R) (ropeginterferon alfa-2b-njft) As the Only Interferon for Adults with Polycythemia Vera

PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting

PharmaEssentia Receives Regulatory Approval in South Korea for BESREMi (ropeginterferon alfa-2b) to Treat Polycythemia Vera

PharmaEssentia Appoints Sulin Shah as U.S. General Counsel, Head of Compliance

PharmaEssentia Appoints Roddy McIlwain as Senior Vice President of U.S. Sales and Marketing

U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for Ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)

PharmaEssentia Resubmits Application to the U.S. FDA for Ropeginterferon alfa-2b-njft to Treat Polycythemia Vera (PV)

Dr. Norio Komatsu Appointed Chairperson of PharmaEssentia Japan

PharmaEssentia Provides U.S. Regulatory Update on Ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)